Su Jeong You
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Su Jeong You has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Eun Hye Lee
2 shared publicationsHye-Ryun Yeh
2 shared publications- Mi-Sun Yum
Department of Pediatrics University of Ulsan College of Medicine Seoul South Korea
2 shared publications Min-Jee Kim
2 shared publicationsSoung Hee Kim
Department of Radiology, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
2 shared publications- Tae-Sung Ko
Department of Pediatrics, Asan Medical Center Children's Hospital, Ulsan University College of Medicine, Seoul, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by The Korean Child Neurology Society in Annals of Child Neurology
- Vol. 34 (4) , 334-336
Visual Hallucinations, Psychotic Symptoms, and Suicidal Ideation Induced by Ethosuximide in a Child with Childhood Absence Epilepsy
- 1 October 2026
- Published by The Korean Child Neurology Society in Annals of Child Neurology
- Vol. 34 (4) , 334-336
Open AccessVisual Hallucinations, Psychotic Symptoms, and Suicidal Ideation Induced by Ethosuximide in a Child with Childhood Absence Epilepsy
- 24 July 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 8-17
A clinical nomogram for predicting drug-resistant epilepsy and its long-term persistence in children: a cohort study
- 24 July 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 8-17
A clinical nomogram for predicting drug-resistant epilepsy and its long-term persistence in children: a cohort study
- Open Access
- 1 July 2024
- Published by The Korean Child Neurology Society in Annals of Child Neurology
- Vol. 32 (3) , 176-180
Comparison of Clinical Characteristics in Patients with Febrile Seizures Based on Prior COVID-19 Infection
Purpose: Febrile seizures (FSs) are neurological events associated with fever, typically occurring in children between 6 months and 5 years of age in the absence of central nervous system infection. Growing evidence suggests that coronavirus disease 2019 (COVID-19) can cause immune system dysregulation. This study compared the clinical characteristics of patients with FS based on whether they had experienced prior COVID-19 infection.Methods: A retrospective analysis was conducted of the medical records of 114 patients with FS who visited Inje University Sanggye Paik Hospital between January 2019 and December 2022. Results: The study cohort included 70 (61.4%) boys and 44 (38.6%) girls, with a mean age of 22.99±11.68 months at seizure onset. Among the 114 patients with FS, 19 had a history of COVID-19, while 95 did not. These groups differed significantly in the interval between the onset of fever and seizure. Specifically, when using a 12-hour threshold for analysis, a significantly greater proportion of patients with a history of COVID-19 exhibited intervals exceeding 12 hours compared to those without such a history. No significant differences were noted regarding sex, age, seizure frequency, personal history of FS, or family history of FS or epilepsy between the groups.Conclusion: Pediatric patients with FS and prior COVID-19 infection exhibited longer intervals between the onset of fever and seizure compared to those without previous COVID-19 infection. This finding suggests that COVID-19 may influence the mechanisms underlying FS. To better understand this relationship, long-term follow-up studies with larger cohorts are warranted.
- 1 July 2024
- Published by The Korean Child Neurology Society in Annals of Child Neurology
- Vol. 32 (3) , 176-180
Open AccessComparison of Clinical Characteristics in Patients with Febrile Seizures Based on Prior COVID-19 Infection
Purpose: Febrile seizures (FSs) are neurological events associated with fever, typically occurring in children between 6 months and 5 years of age in the absence of central nervous system infection. Growing evidence suggests that coronavirus disease 2019 (COVID-19) can cause immune system dysregulation. This study compared the clinical characteristics of patients with FS based on whether they had experienced prior COVID-19 infection.Methods: A retrospective analysis was conducted of the medical records of 114 patients with FS who visited Inje University Sanggye Paik Hospital between January 2019 and December 2022. Results: The study cohort included 70 (61.4%) boys and 44 (38.6%) girls, with a mean age of 22.99±11.68 months at seizure onset. Among the 114 patients with FS, 19 had a history of COVID-19, while 95 did not. These groups differed significantly in the interval between the onset of fever and seizure. Specifically, when using a 12-hour threshold for analysis, a significantly greater proportion of patients with a history of COVID-19 exhibited intervals exceeding 12 hours compared to those without such a history. No significant differences were noted regarding sex, age, seizure frequency, personal history of FS, or family history of FS or epilepsy between the groups.Conclusion: Pediatric patients with FS and prior COVID-19 infection exhibited longer intervals between the onset of fever and seizure compared to those without previous COVID-19 infection. This finding suggests that COVID-19 may influence the mechanisms underlying FS. To better understand this relationship, long-term follow-up studies with larger cohorts are warranted.
- Open Access
- 1 April 2021
- Published by The Korean Child Neurology Society in Annals of Child Neurology
- Vol. 29 (2) , 83-90
Characteristics of Meningitis in Febrile Infants Aged ≤90 Days
- 1 April 2021
- Published by The Korean Child Neurology Society in Annals of Child Neurology
- Vol. 29 (2) , 83-90
Open AccessCharacteristics of Meningitis in Febrile Infants Aged ≤90 Days
- 3 February 2020
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 51 (05) , 354-358
Older Patients May Have More Frequent Seizures among Children Diagnosed as Benign Convulsions with Mild Gastroenteritis
Purpose Benign convulsions with mild gastroenteritis (CwG) is a condition that does not usually require treatment. However, when the patient experiences multiple seizures or prolonged seizures, anticonvulsant treatment may be required. We investigated this study to identify the factors that may influence on the number or duration of seizures at CwG. Methods We retrospectively analyzed the medical records of CwG patients who were admitted to the Department of Pediatrics at Sanggye Paik Hospital. Results A total of 105 children with CwG were enrolled. The mean age was 19.59 ± 7.09 months. The mean duration of seizure was 2.79 ± 5.51 minutes and mean number of seizure was 2.33 ± 1.70. Sixty-nine children had seizures less than twice, whereas 36 experienced three times or more. These groups differed significantly according to age in CwG (18.16 ± 7.08, vs. 22.33 ± 6.34 months, p < 0.05). When patients were divided into two groups based on age in CwG using a cut-off of 20 months, we found significant differences in seizure number (1.91 ± 1.27 vs. 3.11 ± 2.10, p < 0.05). There was also a positive correlation between patient age and frequency of seizures (R = 0.316, p = 0.001). Patients who received anticonvulsants were older (17.60 ± 6.87 vs. 22.04 ± 6.63 months, p < 0.05) and had more frequent (1.59 ± 1.37 vs. 3.26 ± 1.63, p < 0.05) and longer seizures (1.76 ± 2.75 vs. 4.07 ± 7.49 minutes, p < 0.05). Conclusion As the number of seizure in CwG was associated with age, treatment in older children may be required in acute stage.
- 3 February 2020
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 51 (05) , 354-358
Older Patients May Have More Frequent Seizures among Children Diagnosed as Benign Convulsions with Mild Gastroenteritis
Purpose Benign convulsions with mild gastroenteritis (CwG) is a condition that does not usually require treatment. However, when the patient experiences multiple seizures or prolonged seizures, anticonvulsant treatment may be required. We investigated this study to identify the factors that may influence on the number or duration of seizures at CwG. Methods We retrospectively analyzed the medical records of CwG patients who were admitted to the Department of Pediatrics at Sanggye Paik Hospital. Results A total of 105 children with CwG were enrolled. The mean age was 19.59 ± 7.09 months. The mean duration of seizure was 2.79 ± 5.51 minutes and mean number of seizure was 2.33 ± 1.70. Sixty-nine children had seizures less than twice, whereas 36 experienced three times or more. These groups differed significantly according to age in CwG (18.16 ± 7.08, vs. 22.33 ± 6.34 months, p < 0.05). When patients were divided into two groups based on age in CwG using a cut-off of 20 months, we found significant differences in seizure number (1.91 ± 1.27 vs. 3.11 ± 2.10, p < 0.05). There was also a positive correlation between patient age and frequency of seizures (R = 0.316, p = 0.001). Patients who received anticonvulsants were older (17.60 ± 6.87 vs. 22.04 ± 6.63 months, p < 0.05) and had more frequent (1.59 ± 1.37 vs. 3.26 ± 1.63, p < 0.05) and longer seizures (1.76 ± 2.75 vs. 4.07 ± 7.49 minutes, p < 0.05). Conclusion As the number of seizure in CwG was associated with age, treatment in older children may be required in acute stage.
- Open Access
- 1 January 2020
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy Asthma & Respiratory Disease
- Vol. 8 (2) , 102-104
A case of toxic epidermal necrolysis due to topiramate
You SJ, et al. Allergy Asthma Respir Dis. 2020 Apr;8(2):102-104. https://doi.org/10.4168/aard.2020.8.2.102
- 1 January 2020
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy Asthma & Respiratory Disease
- Vol. 8 (2) , 102-104
Open AccessA case of toxic epidermal necrolysis due to topiramate
You SJ, et al. Allergy Asthma Respir Dis. 2020 Apr;8(2):102-104. https://doi.org/10.4168/aard.2020.8.2.102
- 21 October 2019
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 35 (2) , 132-136
Human Herpesvirus-6 may be Neurologically Injurious in Some Immunocompetent Children
Human herpesvirus 6 (HHV-6) can infect the central nervous system in immunocompromised individuals. Less is known, however, about HHV-6 infection in immunocompetent patients. This study evaluated the neurologic features and prognosis of HHV-6 infection in immunocompetent patients. The medical records of patients aged 1 month to 18 years who underwent cerebrospinal fluid examinations and were tested for 6 viruses, including HHV-6, by multiplex polymerase chain reaction were evaluated retrospectively. During the study period, 252 children were included. None had underlying disease and all were immunocompetent. Their mean age at diagnosis was 40.98 ± 47.65 months. Of these 252 patients, 144 (57.1%) were diagnosed with meningitis, 84 (33.3%) with febrile seizure not induced by meningitis, and 24 (9.5%) with encephalitis. Of the 9 patients positive for HHV-6, 3 (33.3%) had encephalitis, 3 (33.3%) had meningitis, 1 (11.1%) had complex febrile seizure, and the other 2 patients had fever alone. Outcomes were worse in the seizure group (Fisher exact test, P = .048), especially in patients with status epilepticus (Fisher exact test, P = .012), than in the other groups. Encephalitis patients with and without HHV-6 differed significantly in age (24.0 ± 10.8 vs 63.4 ± 47.7 months, t-test P < .05), with status epilepticus being more frequent in those with HHV-6 (Fisher exact test, P = .010). All 3 encephalitis patients positive for HHV-6 had neurologic sequelae; 2 who had mild sequelae were treated with antiviral agents and intravenous immunoglobulin. HHV-6 may not be completely benign in immunocompetent children. It can be associated with encephalitis and poor prognosis.
- 21 October 2019
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 35 (2) , 132-136
Human Herpesvirus-6 may be Neurologically Injurious in Some Immunocompetent Children
Human herpesvirus 6 (HHV-6) can infect the central nervous system in immunocompromised individuals. Less is known, however, about HHV-6 infection in immunocompetent patients. This study evaluated the neurologic features and prognosis of HHV-6 infection in immunocompetent patients. The medical records of patients aged 1 month to 18 years who underwent cerebrospinal fluid examinations and were tested for 6 viruses, including HHV-6, by multiplex polymerase chain reaction were evaluated retrospectively. During the study period, 252 children were included. None had underlying disease and all were immunocompetent. Their mean age at diagnosis was 40.98 ± 47.65 months. Of these 252 patients, 144 (57.1%) were diagnosed with meningitis, 84 (33.3%) with febrile seizure not induced by meningitis, and 24 (9.5%) with encephalitis. Of the 9 patients positive for HHV-6, 3 (33.3%) had encephalitis, 3 (33.3%) had meningitis, 1 (11.1%) had complex febrile seizure, and the other 2 patients had fever alone. Outcomes were worse in the seizure group (Fisher exact test, P = .048), especially in patients with status epilepticus (Fisher exact test, P = .012), than in the other groups. Encephalitis patients with and without HHV-6 differed significantly in age (24.0 ± 10.8 vs 63.4 ± 47.7 months, t-test P < .05), with status epilepticus being more frequent in those with HHV-6 (Fisher exact test, P = .010). All 3 encephalitis patients positive for HHV-6 had neurologic sequelae; 2 who had mild sequelae were treated with antiviral agents and intravenous immunoglobulin. HHV-6 may not be completely benign in immunocompetent children. It can be associated with encephalitis and poor prognosis.
- Open Access
- 15 August 2019
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 62 (8) , 312-316
Evaluation of hematologic profile may be needed for patients treated with oxcarbazepine
The major side effects of treatment with oxcarbazepine (OXC) are skin rash and hyponatremia. Hematologic side effects are reported rarely. The aim of this study was to investigate the rate and types of the hematologic side effects of OXC. The medical records of 184 patients diagnosed with epilepsy or movement disorder and on OXC monotherapy, at the Department of Pediatrics of Inje University Sanggye Paik Hospital from July 2001 to July 2018, were retrospectively reviewed. Of the 184 patients, 10 (5.4%) developed leukopenia in addition to pancytopenia and 2 (1.0%) developed pancytopenia. Leukopenia developed in 11 days to 14 years after OXC administration and was more frequent in males than in females (male vs. female, 9 vs. 1; Fisher exact test, P0.05, t -test). OXC-induced leukopenia is not rare and may result in pancytopenia. Patients being treated with OXC should be regularly monitored for abnormal complete blood count profiles.
- 15 August 2019
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 62 (8) , 312-316
Open AccessEvaluation of hematologic profile may be needed for patients treated with oxcarbazepine
The major side effects of treatment with oxcarbazepine (OXC) are skin rash and hyponatremia. Hematologic side effects are reported rarely. The aim of this study was to investigate the rate and types of the hematologic side effects of OXC. The medical records of 184 patients diagnosed with epilepsy or movement disorder and on OXC monotherapy, at the Department of Pediatrics of Inje University Sanggye Paik Hospital from July 2001 to July 2018, were retrospectively reviewed. Of the 184 patients, 10 (5.4%) developed leukopenia in addition to pancytopenia and 2 (1.0%) developed pancytopenia. Leukopenia developed in 11 days to 14 years after OXC administration and was more frequent in males than in females (male vs. female, 9 vs. 1; Fisher exact test, P0.05, t -test). OXC-induced leukopenia is not rare and may result in pancytopenia. Patients being treated with OXC should be regularly monitored for abnormal complete blood count profiles.
- Open Access
- 15 March 2019
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 62 (3) , 108-112
A long-term subacute sclerosing panencephalitis survivor treated with intraventricular interferon-alpha for 13 years
Subacute sclerosing panencephalitis (SSPE) is a rare, progressive, and fatal central nervous system disorder resulting from persistent measles virus infection. Long-term data are scarce, with a maximum follow-up period of 10 years. Interferon-alpha (IFN-α) is a protein that exerts its antiviral activity via enhancement of cellular immune response and is reported to be an effective drug for the treatment of SSPE. However, there is currently no consensus regarding the optimal duration of IFN-α therapy. Here, we present a case report of a patient with SSPE treated with long-term intraventricular IFN-α therapy, which facilitated clinical improvement and neurological stabilization without causing serious adverse effects. To the best of our knowledge, this is one of the longest follow-up studies investigating a patient with SSPE receiving intraventricular INF-α treatment. Further studies are necessary to validate the benefits and safety of long-term intraventricular IFN-α treatment in patients with SSPE.
- 15 March 2019
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 62 (3) , 108-112
Open AccessA long-term subacute sclerosing panencephalitis survivor treated with intraventricular interferon-alpha for 13 years
Subacute sclerosing panencephalitis (SSPE) is a rare, progressive, and fatal central nervous system disorder resulting from persistent measles virus infection. Long-term data are scarce, with a maximum follow-up period of 10 years. Interferon-alpha (IFN-α) is a protein that exerts its antiviral activity via enhancement of cellular immune response and is reported to be an effective drug for the treatment of SSPE. However, there is currently no consensus regarding the optimal duration of IFN-α therapy. Here, we present a case report of a patient with SSPE treated with long-term intraventricular IFN-α therapy, which facilitated clinical improvement and neurological stabilization without causing serious adverse effects. To the best of our knowledge, this is one of the longest follow-up studies investigating a patient with SSPE receiving intraventricular INF-α treatment. Further studies are necessary to validate the benefits and safety of long-term intraventricular IFN-α treatment in patients with SSPE.
- 1 February 2019
- Published by Elsevier in Brain and Development
- Vol. 41 (2) , 158-162
Factors associated with electroencephalographic and clinical remission of benign childhood epilepsy with centrotemporal spikes
- 1 February 2019
- Published by Elsevier in Brain and Development
- Vol. 41 (2) , 158-162
Factors associated with electroencephalographic and clinical remission of benign childhood epilepsy with centrotemporal spikes